Lars Martin Wagner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lars Martin Wagner has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Bhuvana A. Setty
Nationwide Children's Hospital, The Ohio State University, Columbus, OH
6 shared publications - Eric S. Sandler
Division of Hematology and Oncology, Nemours Children's Health , Jacksonville, FL 32207
6 shared publications - Masanori Hayashi
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
6 shared publications - Michael S. Isakoff
University of Connecticut School of Medicine
6 shared publications - Aditi Dhir
Department of Pediatric Hematology‐Oncology University of Miami‐Miller School of Medicine/Jackson Health System‐Holtz Children's Hospital Miami Florida USA
5 shared publications - Avery Bodlak
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
5 shared publications
Latest Publications
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S3. Detailed ctDNA results over the course of the study.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S3. Detailed ctDNA results over the course of the study.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplementary Table S1. Representativeness of Study Participants
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplementary Table S1. Representativeness of Study Participants
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S2. Immunohistochemistry Results and Clinical Benefit
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S2. Immunohistochemistry Results and Clinical Benefit
- 3 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5314-5322
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 3 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5314-5322
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31355
Impact of Duffy‐associated neutrophil count on maintenance chemotherapy management in a child with acute lymphoblastic leukemia
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31355
Impact of Duffy‐associated neutrophil count on maintenance chemotherapy management in a child with acute lymphoblastic leukemia
- Open Access
- 10 September 2024
- Published by Wiley
Impact of Duffy-Associated Neutrophil Count on Maintenance Chemotherapy Management in a Child with Acute Lymphoblastic Leukemia
- 10 September 2024
- Published by Wiley
Open AccessImpact of Duffy-Associated Neutrophil Count on Maintenance Chemotherapy Management in a Child with Acute Lymphoblastic Leukemia
- Open Access
- 31 August 2024
- Published by Wiley
Impact of Duffy-Associated Neutrophil Count on Chemotherapy Management in Pediatric Acute Lymphoblastic Leukemia
Maintenance therapy is critical for successful treatment of pediatric acute lymphoblastic leukemia (ALL). Chemotherapy dosing during maintenance is guided by the absolute neutrophil count, and may be influenced by the rs2814478 polymorphism causing Duffy-associated neutrophil counts (DANC). Breast cancer patients with DANC experience more neutropenia and reduced treatment intensity, despite not having increased infections. To illustrate the potential impact in pediatric ALL, we describe maintenance therapy for a child with DANC. This case raises the possibility that maintenance therapy may be inappropriately reduced in patients with DANC when using conventional guidelines, potentially contributing to disparities in outcomes.
- 31 August 2024
- Published by Wiley
Open AccessImpact of Duffy-Associated Neutrophil Count on Chemotherapy Management in Pediatric Acute Lymphoblastic Leukemia
Maintenance therapy is critical for successful treatment of pediatric acute lymphoblastic leukemia (ALL). Chemotherapy dosing during maintenance is guided by the absolute neutrophil count, and may be influenced by the rs2814478 polymorphism causing Duffy-associated neutrophil counts (DANC). Breast cancer patients with DANC experience more neutropenia and reduced treatment intensity, despite not having increased infections. To illustrate the potential impact in pediatric ALL, we describe maintenance therapy for a child with DANC. This case raises the possibility that maintenance therapy may be inappropriately reduced in patients with DANC when using conventional guidelines, potentially contributing to disparities in outcomes.
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30494
Pediatric renal malignancy diagnosis is associated with significant burden of care for families
Background and objectives: New childhood cancer diagnoses require timely, complex care coordination and cause considerable logistic burden for families. We used renal tumors as a model to examine healthcare utilization and cost following new solid tumor diagnosis.Methods: Children (ages 0–21) with International Classification of Disease (ICD) codes for renal malignancy and subsequent nephrectomy were identified from North Carolina Medicaid claims data (2014–2020). We stratified patients by duration of follow‐up, then quantified healthcare utilization and billing totals.Results: Eighty‐one children met study criteria. Median age at diagnosis was 3 years (interquartile range [IQR]: 1–5). Median family monthly earned income was $0. One month following diagnosis, children cumulatively spent a median of 16 days receiving medical care (IQR: 10–20), 28 days at 3 months (IQR: 21–43), and 50.5 days at 1 year (IQR: 35–94.5). Children cumulatively spent a median 12 days as inpatients during the first 3 months (IQR: 7–17) and 13.5 days at 1 year (IQR: 8.5–37). Children cumulatively completed a median 12 outpatient encounters at 3 months (IQR: 7–17) and 26 at 1 year (IQR: 12–36). At 1 year, median Medicaid claim reimbursements for children with renal malignancy was $50,041 (IQR: $36,670–$80,734).Conclusion: In examining healthcare utilization in children with renal tumor diagnoses, the substantial number of days spent in medical facilities greatly impacts the burden of care on families, especially for those with limited financial resources. Awareness of this logistic strain on families and careful planning to consolidate patient visits may improve the navigability of pediatric cancer regimens for families, particularly those with limited resources.
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30494
Pediatric renal malignancy diagnosis is associated with significant burden of care for families
Background and objectives: New childhood cancer diagnoses require timely, complex care coordination and cause considerable logistic burden for families. We used renal tumors as a model to examine healthcare utilization and cost following new solid tumor diagnosis.Methods: Children (ages 0–21) with International Classification of Disease (ICD) codes for renal malignancy and subsequent nephrectomy were identified from North Carolina Medicaid claims data (2014–2020). We stratified patients by duration of follow‐up, then quantified healthcare utilization and billing totals.Results: Eighty‐one children met study criteria. Median age at diagnosis was 3 years (interquartile range [IQR]: 1–5). Median family monthly earned income was $0. One month following diagnosis, children cumulatively spent a median of 16 days receiving medical care (IQR: 10–20), 28 days at 3 months (IQR: 21–43), and 50.5 days at 1 year (IQR: 35–94.5). Children cumulatively spent a median 12 days as inpatients during the first 3 months (IQR: 7–17) and 13.5 days at 1 year (IQR: 8.5–37). Children cumulatively completed a median 12 outpatient encounters at 3 months (IQR: 7–17) and 26 at 1 year (IQR: 12–36). At 1 year, median Medicaid claim reimbursements for children with renal malignancy was $50,041 (IQR: $36,670–$80,734).Conclusion: In examining healthcare utilization in children with renal tumor diagnoses, the substantial number of days spent in medical facilities greatly impacts the burden of care on families, especially for those with limited financial resources. Awareness of this logistic strain on families and careful planning to consolidate patient visits may improve the navigability of pediatric cancer regimens for families, particularly those with limited resources.
- Open Access
- 5 September 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (11) , e16029
In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues
Glycogen dysregulation is a hallmark of aging, and aberrant glycogen drives metabolic reprogramming and pathogenesis in multiple diseases. However, glycogen heterogeneity in healthy and diseased tissues remains largely unknown. Herein, we describe a method to define spatial glycogen architecture in mouse and human tissues using matrix‐assisted laser desorption/ionization mass spectrometry imaging. This assay provides robust and sensitive spatial glycogen quantification and architecture characterization in the brain, liver, kidney, testis, lung, bladder, and even the bone. Armed with this tool, we interrogated glycogen spatial distribution and architecture in different types of human cancers. We demonstrate that glycogen stores and architecture are heterogeneous among diseases. Additionally, we observe unique hyperphosphorylated glycogen accumulation in Ewing sarcoma, a pediatric bone cancer. Using preclinical models, we correct glycogen hyperphosphorylation in Ewing sarcoma through genetic and pharmacological interventions that ablate in vivo tumor growth, demonstrating the clinical therapeutic potential of targeting glycogen in Ewing sarcoma.
- 5 September 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (11) , e16029
Open AccessIn situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues
Glycogen dysregulation is a hallmark of aging, and aberrant glycogen drives metabolic reprogramming and pathogenesis in multiple diseases. However, glycogen heterogeneity in healthy and diseased tissues remains largely unknown. Herein, we describe a method to define spatial glycogen architecture in mouse and human tissues using matrix‐assisted laser desorption/ionization mass spectrometry imaging. This assay provides robust and sensitive spatial glycogen quantification and architecture characterization in the brain, liver, kidney, testis, lung, bladder, and even the bone. Armed with this tool, we interrogated glycogen spatial distribution and architecture in different types of human cancers. We demonstrate that glycogen stores and architecture are heterogeneous among diseases. Additionally, we observe unique hyperphosphorylated glycogen accumulation in Ewing sarcoma, a pediatric bone cancer. Using preclinical models, we correct glycogen hyperphosphorylation in Ewing sarcoma through genetic and pharmacological interventions that ablate in vivo tumor growth, demonstrating the clinical therapeutic potential of targeting glycogen in Ewing sarcoma.